Logo image of BLTE

BELITE BIO INC - ADR (BLTE) Stock Fundamental Analysis

NASDAQ:BLTE - Nasdaq - US07782B1044 - ADR - Currency: USD

59.465  +2.66 (+4.67%)

Fundamental Rating

3

Taking everything into account, BLTE scores 3 out of 10 in our fundamental rating. BLTE was compared to 195 industry peers in the Pharmaceuticals industry. While BLTE has a great health rating, there are worries on its profitability. BLTE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BLTE has reported negative net income.
In the past 5 years BLTE always reported negative net income.
BLTE had a negative operating cash flow in each of the past 5 years.
BLTE Yearly Net Income VS EBIT VS OCF VS FCFBLTE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 0 0 0 0

1.2 Ratios

BLTE has a Return On Assets (-25.71%) which is comparable to the rest of the industry.
The Return On Equity of BLTE (-26.69%) is better than 67.18% of its industry peers.
Industry RankSector Rank
ROA -25.71%
ROE -26.69%
ROIC N/A
ROA(3y)-28.65%
ROA(5y)-32.2%
ROE(3y)-30.23%
ROE(5y)-34.36%
ROIC(3y)N/A
ROIC(5y)N/A
BLTE Yearly ROA, ROE, ROICBLTE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BLTE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLTE Yearly Profit, Operating, Gross MarginsBLTE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, BLTE has more shares outstanding
There is no outstanding debt for BLTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BLTE Yearly Shares OutstandingBLTE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
BLTE Yearly Total Debt VS Total AssetsBLTE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

There is no outstanding debt for BLTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
BLTE Yearly LT Debt VS Equity VS FCFBLTE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 24.30 indicates that BLTE has no problem at all paying its short term obligations.
The Current ratio of BLTE (24.30) is better than 94.36% of its industry peers.
A Quick Ratio of 24.30 indicates that BLTE has no problem at all paying its short term obligations.
The Quick ratio of BLTE (24.30) is better than 94.36% of its industry peers.
Industry RankSector Rank
Current Ratio 24.3
Quick Ratio 24.3
BLTE Yearly Current Assets VS Current LiabilitesBLTE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for BLTE have decreased strongly by -15.25% in the last year.
EPS 1Y (TTM)-15.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 25.02% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-44.64%
EPS Next 2Y-28.38%
EPS Next 3Y14.66%
EPS Next 5Y25.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BLTE Yearly Revenue VS EstimatesBLTE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
BLTE Yearly EPS VS EstimatesBLTE Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BLTE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BLTE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLTE Price Earnings VS Forward Price EarningsBLTE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLTE Per share dataBLTE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

BLTE's earnings are expected to grow with 14.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.38%
EPS Next 3Y14.66%

More info and screens

0

5. Dividend

5.1 Amount

BLTE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BELITE BIO INC - ADR

NASDAQ:BLTE (7/3/2025, 7:05:17 PM)

59.465

+2.66 (+4.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)N/A N/A
Inst Owners0.74%
Inst Owner Change-4.79%
Ins Owners1.4%
Ins Owner ChangeN/A
Market Cap1.92B
Analysts83.64
Price Target86.7 (45.8%)
Short Float %1.06%
Short Ratio4.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-10.02%
Min EPS beat(2)-18.12%
Max EPS beat(2)-1.93%
EPS beat(4)1
Avg EPS beat(4)-8.9%
Min EPS beat(4)-20.25%
Max EPS beat(4)4.68%
EPS beat(8)4
Avg EPS beat(8)-2.32%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.03%
EPS NY rev (1m)-9.37%
EPS NY rev (3m)-25.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.16
P/tB 12.16
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)-1.94
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS4.89
TBVpS4.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.71%
ROE -26.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.65%
ROA(5y)-32.2%
ROE(3y)-30.23%
ROE(5y)-34.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.3
Quick Ratio 24.3
Altman-Z N/A
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)232.78%
Cap/Depr(5y)186.33%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
EPS Next Y-44.64%
EPS Next 2Y-28.38%
EPS Next 3Y14.66%
EPS Next 5Y25.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-41.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y3.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.33%
OCF growth 3YN/A
OCF growth 5YN/A